In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $3.74.
Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Tempest Therapeutics, and SAGE Therapeutics. According to TipRanks, Farmer has an average return of 22.7% and a 60.56% success rate on recommended stocks.
Tempest Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.75, implying a 454.81% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.77 and a one-year low of $0.17. Currently, Tempest Therapeutics has an average volume of 774K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tempest Therapeutics (TPST) Company Description:
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
Read More on TPST:
- Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Scotiabank starts Tempest at Outperform on liver cancer potential
- Tempest Therapeutics initiated with an Outperform at Scotiabank
- Tempest Therapeutics presents new data on TPST-1120 at SITC meeting
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
